Johnson & Johnson Earnings Call Signals Confident Growth

Johnson & Johnson ((JNJ)) has held its Q2 earnings call. Read on for the main highlights of the call.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Johnson & Johnson’s latest earnings call struck an upbeat tone, as management highlighted broad‑based growth and a powerful slate of innovative medicines. While legacy product declines, MedTech pockets of weakness and higher expenses weighed on certain metrics, executives framed these as manageable headwinds against a backdrop of rising guidance, robust cash generation and a rich pipeline.

Strong Q2 Revenue and Upgraded Outlook

Johnson & Johnson reported worldwide Q2 sales of $25.3 billion, with operational growth of 5.6% that underscored steady demand across its portfolio. On the back of this performance, the company raised full‑year 2026 operational sales growth guidance to 6.5%–7.1%, implying roughly $100.6 billion in revenue at the midpoint.

Innovative Medicine Momentum Despite STELARA Drag

Innovative Medicine sales reached $16.4 billion, rising 6.8% operationally even after a roughly 760‑basis‑point headwind from the steep STELARA decline. Excluding STELARA, management said the business grew at a double‑digit pace, while maintaining a strong adjusted income before tax margin of 42.5%.

Multiple High‑Growth Blockbusters Drive Performance

Several key therapies delivered standout growth, reinforcing the strength of Johnson & Johnson’s newer franchises. TREMFYA surged 71%, while oncology and hematology assets such as CARVYKTI, TECVAYLI, TALVEY, RYBREVANT and DARZALEX posted robust double‑digit gains, with DARZALEX alone climbing about 17.6% to more than $4 billion in sales.

New Launches ICOTYDE and INLEXZO Gain Traction

Fresh launches are ramping quickly, adding new pillars to the portfolio. ICOTYDE logged over 18,000 prescriptions with around 11,000 patients starting therapy and more than 6,000 unique prescribers, supported by rapid commercial coverage, while INLEXZO saw nearly one in three eligible patients begin treatment and quarterly sales more than doubled versus Q1.

MedTech Growth Balanced by Innovation Investments

MedTech delivered operational sales growth of 3.6% to $8.9 billion, with notable momentum in several product lines. The VARIPULSE pulsed field ablation system has now treated over 85,000 AFib patients, Shockwave grew 14.7%, and vision posted 5.6% growth, aided by premium IOLs and ACUVUE lenses, as the company also advanced robotics and surgical stapling platforms.

Improving EPS and Cash Flow Fundamentals

Adjusted net earnings reached $7.1 billion and adjusted diluted EPS came in at $2.90, up 4.7% year on year, reflecting solid profitability despite investment spending. Free cash flow year‑to‑date improved to about $8.7 billion, with management indicating it is on track to approach $21 billion for the full year, backed by a cash and securities position of roughly $21 billion.

Pipeline and M&A Provide Additional Upside

The company pointed to a busy second half for its pipeline, including an FDA decision for IMAAVY and multiple data readouts for assets like TECVAYLI plus TALVEY, pasritamig and J&J 6143. Johnson & Johnson also announced a planned acquisition of Firefly Bio to bolster its oncology platform, alongside continued strategic investment in research and development.

Operating Leverage and Margin Outlook Brighten

Management now expects about a 75‑basis‑point improvement in adjusted pre‑tax operating margin in 2026, up from a prior view of more than 50 basis points. This enhanced margin outlook is supported by operating efficiencies and assumptions around tariff recoupment, signaling better leverage even as the company funds growth initiatives.

STELARA Decline Creates a Significant Revenue Drag

The rapid erosion of STELARA remains a notable headwind, with sales down 55.7% year over year amid biosimilar competition and shifts in treatment patterns. STELARA alone represented an estimated 460‑basis‑point drag on worldwide sales growth and about a 760‑basis‑point headwind to Innovative Medicine, forcing faster diversification.

MedTech Headwinds in Cardiovascular and Abiomed

Cardiovascular growth slowed to 3.1%, falling below recent trends and highlighting emerging pressure in this segment. Abiomed sales declined 2% in Q2 as physicians became more selective following a neutral external trial, dampening U.S. procedure volumes and clouding near‑term visibility for that business.

Inventory and Regional Pressures, Especially in China

Electrophysiology results were tempered by competitive pulsed field ablation offerings and an estimated China inventory impact of roughly 400 basis points. Surgery also faced about a 40‑basis‑point drag from divestitures as well as persistent value‑based purchasing and competitive challenges in China and in energy devices and endo cutters.

GAAP Earnings Affected by Higher Expenses and Taxes

On a GAAP basis, net earnings slipped to $5.5 billion, with diluted EPS edging down to $2.27 from $2.29 a year earlier. Other income and expense swung to a larger net expense of $331 million and the effective tax rate climbed to 18.0% from 14.7%, reflecting litigation, restructuring‑related impairments and separation costs.

Margin Pressure from SG&A Launch Investments

Enterprise adjusted income before tax margin eased slightly from 34.5% to 34.2%, while Innovative Medicine and MedTech margins each dipped 20 basis points. Management attributed roughly 60 basis points of SG&A deleveraging to heavier launch investments, indicating some near‑term margin pressure tied to building future growth engines.

Uncertainty Around Event‑Driven Trials and Abiomed Timing

Executives cautioned that certain key studies are event‑driven, leaving readout timing hard to predict and potentially pushing milestones into late 2026 or 2027. Recovery at Abiomed is similarly tied to physician behavior and the PROTECT IV study, with clarity on that franchise not expected until 2027.

Persistent Competitive Pressures Across Select Segments

Competitive dynamics remain intense in several categories, including energy devices, endo cutters and select biologics. Biosimilar competition to STELARA is materially disrupting legacy revenue streams, even as shifts in U.S. patient mix and inventory patterns help partially offset these pressures in some areas.

Raised Guidance and Strengthened 2026 Outlook

Looking ahead, Johnson & Johnson raised its full‑year 2026 guidance, now forecasting operational sales growth of 6.5%–7.1% and reported sales growth of 7.0%–7.6%, with a modest foreign‑exchange drag and a benefit from a 53rd week. The company projects adjusted operational EPS of $11.50–$11.65 and reported EPS of $11.60–$11.75, alongside free cash flow expected to approach about $21 billion.

In sum, Johnson & Johnson’s earnings call balanced clear challenges with a confident growth narrative driven by innovative medicines, new launches and solid cash generation. For investors, the raised guidance, improving margin outlook and rich pipeline suggest the company is leaning into its strengths to offset legacy erosion and competitive pressures.

Johnson & Johnson’s Earnings Call Signals Confident Growth Path